article thumbnail

5 Litigation Funding Trends To Note In 2024

IP Law 360

Over the next year and beyond, litigation funding will continue to evolve in ways that affect attorneys and the larger litigation landscape, from the growth of a secondary market for funded claims, to rising interest rates restricting the availability of capital, says Jeffery Lula at GLS Capital.

article thumbnail

Abbott Settles TM Suit Over Gray Market Diabetes Test Strips

IP Law 360

Abbott Laboratories told a New York federal judge Friday that the company has settled what remains of its trademark litigation campaign against makers of gray market diabetes test strips that has been going on since 2015.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lessons For Biosimilar And Biologic Antitrust Litigation

IP Law 360

Aaron Marks at Cohen Milstein considers emerging ways in which biosimilar markets differ from traditional small-molecule drug markets, and recommends how pharmaceutical antitrust litigators can account for these market dynamics in biosimilar-delay cases.

article thumbnail

Litigation as a Source of Profit? Non-Practicing Entities and Patent Litigation

IPilogue

Litigation is almost always recommended to be avoided , whether because of the sheer amount of time needed to get a court date, the expensive costs for the client and law firm, or the risks associated with receiving an unfavorable judgement. Michelle Mao is an incoming 2L JD student at Osgoode Hall Law school and an IPilogue Writer.

article thumbnail

Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

JD Supra Law

In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price Competition and Innovation Act (BPCIA), post-grant disputes on biologic drug patents before the United States Patent and Trademark Office (USPTO), and proposed legislation (..)

article thumbnail

Laura Loomer Loses Litigation (Again)–Loomer v. Zuckerberg

Technology & Marketing Law Blog

I’m sure this ruling won’t the last one in this case or in Loomer’s broader litigation campaign. The post Laura Loomer Loses Litigation (Again)–Loomer v. The post Laura Loomer Loses Litigation (Again)–Loomer v. Zuckerberg appeared first on Technology & Marketing Law Blog. The complaint.

article thumbnail

Patent Linkage Litigation in China: A Two-Year Review

IP Tech Blog

An important part of the amendment is the introduction by Article 76 of the patent linkage system in China – a system for litigation of drug patents prior to market entry of generics, similar to that provided by the Hatch Waxman Act in the US. On June 1, 2021, the Fourth Amendment to the Chinese Patent Law became effective.